Literature DB >> 10485353

Natural Haemophilus influenzae type b capsular polysaccharide antibodies in 412 infants and children from West Africa (Burkina-Faso) and France: a cross-sectional serosurvey.

F Ballereau1, M Speich, V Apaire-Marchais.   

Abstract

Prior to possible introduction of large-scale vaccination programmes, an estimation and comparison of naturally acquired immunity against Haemophilus influenzae type b (Hib) was carried out in two populations of age-stratified infants and children (from birth to 14 years old) in Burkina-Faso (West Africa) (n = 206) and France (n = 206). Hib capsular polysaccharide antibodies were detected by an ELISA method. The difference in the percentages of minimum protective levels for the two populations were not significant (0.15 microg/ml) for newborns (0-1 month) but became significant as early as 2 to 3 months of age (p < 0.01) when lower levels were found among infants from Burkina-Faso. Subsequently, the percentages in both countries remained low until 11 months of age and showed no significant differences. For children between 12 and 35 months, the results > or = 0.15 microg/ml were significantly higher in France (p < or = 0.05). From 36 months, the percentage of minimum seropositivity increased in Burkina-Faso, so that the difference was no longer significant. In each country, the percentage of children with the minimum protective level varied significantly (p < or = 0.05) according to age (0-47 months). None of the children from Burkina-Faso or France had antibody levels > 1.0 microg/ml before one year of age. Thereafter, only 9.51% of French children in the 12- to 17-month age stratum and 19.2% over 4 years of age had antibody levels > 1.0 microg/ml. There were no non-detectable results for children over 4 years of age, and the means for natural detectable Hib CP antibodies were > 0.15 microg/ml for both populations. Hib invasive infections depend on climate, socioeconomic status and ethnic and genetic factors. In Burkina-Faso, the large number of infants and children under 4 years of age susceptible to Hib infections suggests that large scale vaccination programmes are needed soon after birth. However, it would first be necessary to evaluate such factors as the frequency of Hib diseases in this population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485353     DOI: 10.1023/a:1007668003578

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  27 in total

1.  Protective effect of breastfeeding on invasive Haemophilus influenzae infection: a case-control study in Swedish preschool children.

Authors:  S A Silfverdal; L Bodin; S Hugosson; O Garpenholt; B Werner; E Esbjörner; B Lindquist; P Olcén
Journal:  Int J Epidemiol       Date:  1997-04       Impact factor: 7.196

2.  Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Hib-HB Vaccine Study Group.

Authors:  D J West; T M Hesley; L C Jonas; L K Feeley; S R Bird; P Burke; J C Sadoff
Journal:  Pediatr Infect Dis J       Date:  1997-06       Impact factor: 2.129

3.  Evaluation of immunogenicity and tolerance of single dose haemophilus influenzae type B (PRP-T) vaccine.

Authors:  D Acharya; A Desai; N Nanavaty; A Pandit; V Patel; J Shah; N Shendurnikar; S Singh; A Taneja; S Vani
Journal:  Indian Pediatr       Date:  1995-10       Impact factor: 1.411

4.  Expression of Haemophilus influenzae type b idiotype 1 on naturally acquired antibodies.

Authors:  M Ulanova; M Hahn-Zoric; Y L Lau; A Lucas; L A Hanson
Journal:  Clin Exp Immunol       Date:  1996-09       Impact factor: 4.330

5.  The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines.

Authors:  J B Robbins; R Schneerson; P Anderson; D H Smith
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

Review 6.  Anti-capsular polysaccharide antibody deficiency states.

Authors:  G T Rijkers; L A Sanders; B J Zegers
Journal:  Immunodeficiency       Date:  1993

7.  An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides.

Authors:  A Sutton; W F Vann; A B Karpas; K E Stein; R Schneerson
Journal:  J Immunol Methods       Date:  1985-10-10       Impact factor: 2.303

8.  The acquisition of anti-pneumococcal capsular polysaccharide Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK.

Authors:  M Hazlewood; R Nusrat; D S Kumararatne; M Goodall; C Raykundalia; D G Wang; H J Joyce; A Milford-Ward; M Forte; A Pahor
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children.

Authors:  D W Scheifele; W Meekison; R Guasparini; A Roberts; L Barreto; J Thipphawong; S Wiltsey
Journal:  Vaccine       Date:  1995-01       Impact factor: 3.641

10.  World-wide strategies for immunization against invasive Haemophilus influenzae type b disease.

Authors:  S Iwarson
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

View more
  1 in total

1.  The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal.

Authors:  Andrew S J Marshall; Charlotte I S Barker; Anoop S Pulickal; Elizabeth Kibwana; Samir C Gautam; Elizabeth A Clutterbuck; Stephen M Thorson; Shrijana Shrestha; Neelam Adhikari; Andrew J Pollard; Dominic F Kelly
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.